WO2007101371A1 - Préparation et utilisation d'esters d'acide purine bis-aminés - Google Patents

Préparation et utilisation d'esters d'acide purine bis-aminés Download PDF

Info

Publication number
WO2007101371A1
WO2007101371A1 PCT/CN2006/000663 CN2006000663W WO2007101371A1 WO 2007101371 A1 WO2007101371 A1 WO 2007101371A1 CN 2006000663 W CN2006000663 W CN 2006000663W WO 2007101371 A1 WO2007101371 A1 WO 2007101371A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
acid
adenine
bis
tert
Prior art date
Application number
PCT/CN2006/000663
Other languages
English (en)
Chinese (zh)
Inventor
Yushe Yang
Xiaozhong Fu
Zhan Li
Ruyun Ji
Original Assignee
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Nanjing Changao Pharmaceutical Science & Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Nanjing Changao Pharmaceutical Science & Technology Co., Ltd. filed Critical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Publication of WO2007101371A1 publication Critical patent/WO2007101371A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • Hepatitis B is a disease caused by hepatitis B virus (HBV) that is seriously harmful to human health. According to statistics, there are about 350 million chronic HBV carriers in the world, and about 1 million people die each year from diseases caused by HBV. About 120 million people in China are carriers of hepatitis B virus, 28 million hepatitis B patients, and one-third of hepatitis B patients will evolve into chronic hepatitis, cirrhosis or primary liver cancer (HCC).
  • HBV hepatitis B virus
  • the main drugs for the treatment of chronic hepatitis B include interferons, nucleoside antiviral drugs and immunomodulators.
  • Nucleoside antiviral drugs are inhibitors of viral DNA polymerases or reverse transcriptases that stop the synthesis of viral DNA strands and thereby inhibit viral replication.
  • nucleoside anti-HBV drugs acyclic nucleoside phosphonates have an important role as analogs of nucleoside 5'-monophosphates, which can bypass rate limiting during nucleoside analog activation.
  • the primary phosphorylation reaction therefore, also has an inhibitory effect on DNA viruses that do not encode viral thymidine kinase (TK), with a broader spectrum of antiviral activity (Erik De Clercq Nature Rev. 2002, 1, 13).
  • TK viral thymidine kinase
  • the structure of the compound is different from that of the L-nucleoside drug, no cross-resistance is generated between the clinically applied L-nucleoside anti-HBV drug such as lamivudine. (Doo E Gastroenterology 2001, 120:1000; Das, KJ Virol 2001, 75:4771) 0 Because of these characteristics, acyclic nucleoside phosphonates represent a class of highly promising antiviral drugs.
  • Adefovir diputelohydroquinone (bis(POM)PMEA, abbreviated as ADV) is a double of 9-[2-(phosphonodecyloxy)ethyl]adenine adefovir (PMEA, Adefovir)
  • PMEA Adefovir
  • ADV has strong antiviral activity against hepatitis B virus (HBV), duck hepatitis B virus (DHBV), and variant hepatitis B virus (YMDD) resistant to lamivudine in vitro and in vivo (Yen MF. Expert Opin Pharmacother. 2004, 5 (11): 2361-7 )» Clinical studies have shown that this drug can significantly improve the liver histology of patients, reduce serum HBV-DNA and transaminase levels, increase the conversion of e antigen (HBeAg), and regardless of the state of HBeAg, Genotype, ethnic differences, or the presence or absence of a variant virus resistant to lamivudine did not affect ADV's anti-HBV activity (Anneke K Raney.
  • ADV applications also have the following major defects: (1) Chemical instability, which is highly sensitive to serum enzyme-mediated hydrolysis and does not effectively increase drug concentration at the site of action (Pieter Annaert, Pharmaceutical Research. 1997, 14(4) : 492-496 ); (2) The transport of one molecule of nucleic acid requires the release of two equivalents of potentially toxic formaldehyde and pivalic acid (Jae-Taeg Hwang. Drugs of the Future 2004, 29(2); 163-177).
  • the new generation of adefovir prodrugs are designed to increase the metabolic stability of the drug, prolong the duration of action, increase the bioavailability of the drug, and reduce the toxicity of the drug.
  • Human peptide transporters are an integrated cytoplasmic membrane protein that mediates the absorption of di- and tripeptides in humans and belongs to the family of proton-dependent oligopeptide transporters. At present, two human peptide transporters (PepTl, PepT2) with transport activity are cloned and functionally confirmed. PepTl is called intestinal peptide transporter, which is mainly present on the comb membrane of intestinal epithelial cells, and mediates the reverse concentration. The gradient of the substrate-proton co-transport process, the natural L-amino acid is its suitable transport substrate (Isabbel Rubio-Aliaga TRENDS in Pharmacological Sciences, 2002, 23(9): 434-440).
  • amino acid ester modification methods have been used for antiviral nucleoside derivatives to improve bioavailability and enhance drug efficacy, such as acyclovir and ganciclovir proline ester prodrugs L. -Valaciclovir and L-Valganciclovir increased the bioavailability of the original drug from 6% to 20% to 63% and 61%, respectively (Birger Brodin. Pharmacology & Toxicology. 2002, 90: 285-29; Raymund R Razonable, Expert Rev. Anti-infect. Ther. 2004, 2 (1): 27-42 ).
  • the penicillin double L-valine and isoleucine ester derivatives developed by MEDIVIR AB can significantly improve the bioavailability of the original drug and make the drug resistant to varicella virus, scorpion virus and EB-virus.
  • Role Per Engelhardt, US 0020188125
  • the L-valine ester derivative BRL 44385 of 9-(3-hydroxypropyl-1-oxo)guanine developed by Smithline Beecham can improve the bioavailability of the original drug.
  • the drug has a potent inhibitory effect on DNA viruses (parotid virus 1/2, varicella virus, cytomegalovirus, hepatitis B virus, etc.) (Harnden, Michael, WO9509855).
  • One object of the present invention is to provide novel terpenoids having antiviral activity, particularly anti-hepatitis B (HBV) and AIDS (HIV) virus activity, and pharmaceutically acceptable salts thereof.
  • Another object of the present invention is to provide a process for the preparation of the above novel anthraquinone compound having antiviral activity, particularly against hepatitis B and HIV virus activity, and a pharmaceutically acceptable salt thereof.
  • a further object of the present invention is to provide the use of such compounds and their salts as active substances in the manufacture of a medicament for the treatment of infectious diseases caused by viral infectious diseases, in particular HBV and HIV viruses.
  • the present invention provides an anthraquinone diaryl acid ester of the formula (I) and a pharmacologically acceptable inorganic or organic salt thereof:
  • Ri is an amino group
  • R 2 is an amino-protected or free L-form amino acid; n is 0 or 1; X is 0 or S.
  • the present invention also provides two processes for preparing a bismuth compound bisamino acid ester having the structure of the above formula (I) and a salt thereof.
  • Method 1 Perform Process I as follows:
  • DCMC ⁇ , ⁇ '-dicyclohexyl-4-morphine-oxime
  • DBU 1,8-two Azabicyclo[5,4,0]undec-7-ene
  • N-tert-butoxy-reactive (BOC) L-amino acid ester N-tert-butoxycarbonyl L-amino acid and 2-bromoethanol in an aprotic solvent in the presence of dicyclohexylcarbodiimide (DCC) and indole, indole-diaminopyridine (DMAP), in 0 ⁇ Reacting at 25 ° C for 6-24 hours to obtain N-tert-butoxycarbonyl L-amino acid bromoethyl ester; or
  • N-tert-butoxycarbonyl L-amino acid is reacted in isobutyl chloroformate, N-methylmorpholine, hydrogen sulfide gas at a low temperature of -20 - -10 ° C for 1-4 hours to obtain N-tert-butoxycarbonyl group.
  • a corresponding pharmaceutically acceptable salt is prepared as needed.
  • the guanidine compound trihydrochloride is freed with sodium hydrogencarbonate, sodium carbonate or the like and formed into a sulfate, a phosphate, a lemon with three equivalents of a mineral acid such as sulfuric acid, phosphoric acid and an organic acid such as citric acid or maleic acid.
  • the citrate and maleate are prepared in a pharmaceutically acceptable manner according to methods known in the art. (Method 2: Flow II is carried out according to Scheme II below)
  • a Oxalyl chloride, hydrazine, ⁇ '-diethyl hydrazide (DEF), 0 ⁇ 50 ° C, 0.5 ⁇ 4.5 hours; b. N, N-dimethylaminopyridine (DMAP), dicyclohexylcarba Amine (DCC), 0 ⁇ 25°C, 6 ⁇ 24 hours; c. Pyridine, triethylamine, 0 ⁇ 25°C, 1 - 10 hours; d. Saturated hydrogen chloride/1,4-dioxane or Acetyl chloride / sterol, -10 ⁇ 25 ° C, 0.5 ⁇ 6 hours.
  • DMAP N-dimethylaminopyridine
  • DCC dicyclohexylcarba Amine
  • Method two includes the following steps: (1) 9-[ 2 _ (phosphonomethoxy)ethyl] adenine in an inert solvent in the presence of a halogenating agent oxalyl chloride and a catalyst, hydrazine, ⁇ '-diethyl hydrazide, 0 to 50 °C, the reaction is carried out for 0.5 to 4.5 hours to obtain a dichlorophosphonate of 9-[2-(phosphonomethoxy)ethyl]adenine.
  • N-tert-butoxycarbonyl L-amino acid and ethylene glycol in an aprotic solvent in the presence of dicyclohexylcarbodiimide and indole, indole-diamidopyridine, at 0-25 ° C From 6 to 24 hours, N-tert-butoxycarbonyl L-amino acid-hydroxyethyl ester was obtained.
  • the product compound obtained in the above step (3) is in a polar or non-polar solvent in the presence of hydrogen chloride-saturated 1, 4-dioxane or acetyl chloride/nonanol at -10 to 25°. C, the reaction is carried out for 0.5 to 6 hours to obtain a product compound.
  • a corresponding pharmaceutically acceptable salt is prepared as needed.
  • the guanidine compound trihydrochloride is freed with sodium hydrogencarbonate, sodium carbonate or the like and formed into a sulfate, a phosphate, and a triple equivalent of a mineral acid such as sulfuric acid, phosphoric acid, and an organic acid such as citric acid or maleic acid.
  • Citrate and maleate salts and the like are prepared as pharmaceutically acceptable salts by methods known in the art.
  • the present invention further provides the use of the adefovir bisphosphonate compound of the formula (I) and a salt thereof for the preparation of a medicament for treating an infectious disease caused by a viral infectious disease, particularly a hepatitis B virus.
  • the pharmacologically acceptable salt of the compound of the present invention specifically includes a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid or phosphoric acid, and tannic acid, acetic acid, propionic acid, oxalic acid, and propylene.
  • Acid succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid
  • An acid addition salt of an acidic acid such as citric acid, picric acid, methanesulfonic acid or ethanesulfonic acid with an acidic amino acid such as aspartic acid or glutamic acid, or a salt formed with a base such as sodium, potassium, calcium or aluminum.
  • a salt of an inorganic base an ammonium salt, a methylamine salt, an ethylamine salt, an ethanolamine salt or the like, or a salt formed with a basic amino acid such as lysine, arginine or ornithine.
  • Representative examples of the compound of the formula (I) of the present invention are as follows:
  • the steroid bi-amino acid esters and pharmacologically acceptable salts thereof claimed in the present invention have a function of treating infectious diseases caused by viral infectious diseases, particularly HBV and HIV viruses.
  • the bismuth compound diamino acid ester and the pharmacologically acceptable salt thereof claimed in the present invention have activity similar to or stronger than those of the nucleoside small molecule anti-HBV drug of the prior art for treating viral infectious diseases. Therefore, these compounds are useful for the preparation of novel drugs for the treatment of viral infectious diseases, particularly infectious diseases caused by HBV and HIV viruses.
  • BEST MODE FOR CARRYING OUT THE INVENTION The present invention will be further illustrated by the following examples, but these examples are in no way intended to limit the invention.
  • the compounds of the invention can be prepared by two methods.
  • the compound of the invention is prepared according to method one:
  • the optimum conditions are tetrahydrofuran as a solvent, and the reaction is carried out at -20 to 10 for 2 to 4 hours.
  • the obtained product and 1,2-dibromoethane are in an aprotic solvent such as toluene, dichlorodecane, chloroform or tetrahydrofuran in the presence of sodium hydride, sodium t-butoxide, lithium t-butoxide, sodium ethoxide or the like.
  • the reaction is carried out at -40 to 10 ° C for 0.5 to 10 hours.
  • the optimum reaction conditions are as follows: tetrahydrofuran is used as a solvent in the presence of sodium hydride at -20 to 0 ° C for 2 to 5 hours.
  • N-tert-Butoxycarbonyl L-aminothiocarboxylic acid-2-bromoethyl ester was obtained.
  • N-tert-butoxycarbonyl (BOC) L-amino acid and bromochloromethane and chlorosulfonate should be obtained as chloropurinyl chlorosulfonate in an inert solvent-water two-phase system (dichloromethane-water, chloroform) - in water, carbon disulfide-water, carbon tetrachloride-water, etc., in the presence of phase transfer catalyst, tetra-n-butylammonium hydrogen sulfate, tetra-n-butylammonium bromide, react at -20 ⁇ 25 °C 0.5 ⁇ After 24 hours, a chloromethyl ester of N-tert-butoxycarbonyl L-amino acid was obtained.
  • the optimum reaction conditions are dichloromethane-water as the reaction system, and tetra-n-butylammonium hydrogen sulfate as the phase transfer catalyst, and the reaction is carried out at 0 to 15 ° C for 6 to 12 hours.
  • Compounds 1 to 10 are present in a polar solvent such as ethyl acetate, isopropyl acetate or 1,4-dioxane in the presence of hydrogen chloride saturated 1,4-dioxane or acetyl chloride/nonanol.
  • the reaction is carried out at -20 - 25 ° C for 0.5-12 hours to obtain compounds 11-20.
  • the optimum reaction conditions are as follows: 1,4-dioxane is used as a reaction solvent, and the reaction is carried out at 0 to 10 ° C for 3 to 6 hours in the presence of a hydrogen chloride-saturated 1,4-dioxane.
  • the hydrazine compound trihydrochloride is freed with sodium hydrogencarbonate, sodium carbonate or the like and forms a sulfate, a phosphate, a citrate with three equivalents of a mineral acid such as sulfuric acid, phosphoric acid and an organic acid such as citric acid, maleic acid or the like.
  • maleate or the like is prepared into a pharmaceutically acceptable salt by a conventional method.
  • the compound of the invention is prepared according to method two:
  • N-tert-butoxycarbonyl L-amino acid and ethylene glycol in a non-polar solvent such as toluene, dichlorodecane, chloroform or tetrahydrofuran, in 1 ⁇ ,: ⁇ -diaminopyridine, dicyclohexylcarbal The reaction is carried out at 0-25 °C for 6-24 hours in the presence of imine. The optimum conditions are to react with dichloromethane as solvent at 10-25 °C for 12-24 hours to obtain N-tert-butoxycarbonyl L-amino acid-hydroxyl. Ethyl ester. '
  • Compounds 21 to 25 are saturated with 1, 4 - dioxane or B in a nonpolar solvent such as 1, 4-dioxane, ethyl acetate, isopropyl acetate or dichlorodecane.
  • a nonpolar solvent such as 1, 4-dioxane, ethyl acetate, isopropyl acetate or dichlorodecane.
  • the reaction is carried out at -10 to 100 ° C for 0.5-6 hours.
  • the optimum reaction conditions are as follows: 1, 4-dioxane as solvent in hydrogen chloride saturation under 1, 4-dioxane conditions , reacting at 0 ⁇ 10 °C for 2 ⁇ 4 hours to obtain compounds 26 ⁇ 30.
  • reaction solvent was evaporated to dryness under reduced pressure, and ethyl acetate (20 ml) was added to the residue, and the mixture was allowed to stand at -5 to 0 ° C for 6 hours, and the insoluble materials were filtered off, and the filtrate was washed with 1% citric acid, water and saturated brine, and anhydrous sodium sulfate. The mixture was dried, filtered, and the filtrate was evaporated,jjjjjjjjjjjjjj Yield: 15.17%.
  • reaction solvent was evaporated to dryness under reduced pressure, and ethyl acetate (20 ml) was added to the residue, and the mixture was allowed to stand at -5 to 0 ° C for 6 hours, and the insoluble material was filtered off, and the filtrate was washed with 1% citric acid, 7 and saturated brine, anhydrous sodium sulfate. The mixture was dried, filtered, and the filtrate was evaporated,jjjjjjj Yield: 13.15%.
  • the ⁇ -tert-butoxycarbonyl-L-proline (2.50 g, 0.0115 mol) was dissolved in 25 ml of dry tetrahydrofuran, cooled to -15 ° C with a water-salt bath, and N-methylmorpholine (11.54 g, 0.0575 mol) and isobutyl chlorodecanoate (1.74 g, 0.0126 mol), and the system was stirred for 30 minutes.
  • the temperature is kept below -15 °C, and the hydrogen peroxide gas is introduced into the system.
  • the aeration time lasts for 1.5-2 hours. After the hydrogen sulfide gas in the system is absorbed to saturation, the reaction is kept for 2 hours to complete the reaction. .
  • reaction solvent was evaporated to dryness under reduced pressure, and ethyl acetate (20 ml, ethyl acetate) was added to the residue, and the mixture was allowed to stand at -5 to 0 ° C, and the insoluble materials were filtered off.
  • the filtrate was washed with 10 ⁇ 2 ml of 1% citric acid, 7 J and saturated brine, dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated. EtOAc m. Yield: 13.09%.
  • N-tert-butoxy-L-phenylalanine was used as a starting material, and was prepared in a similar manner to that of Example 3 to obtain a white amber compound ( 2S, 2' S ) -9- ⁇ 2-[0 , 0'-bis[(2-tert-butoxycarbonylamino-3-phenylpropionylthio)ethyl]phosphonohydrazide]ethyl ⁇ adenine 61 mg. Yield: 12.67 %.
  • ⁇ -tert-Butoxycarbonyl-L-proline was used as a starting material, which was prepared in a similar manner to that of Example 3 to give a pale brown oily compound (2S, 2's) -9- ⁇ 2-[0,0 '-Bis[(1-tert-butoxycarbonyl-2-pyrrolidinylsulfonyl)ethyl]phosphonohydrazide]ethyl ⁇ adenine 55 mg, Yield: 18.61%.
  • ⁇ -tert-butoxy-l-isoleucine was used as a starting material, and was prepared in a similar manner to that of Example 3 to give a white foamy compound (2S, 2's) -9- ⁇ 2-[0 , 0'-bis[(2-tert-butoxycarbonylamino-3-mercapto-valerylthio)ethyl]phosphonomethoxy]ethyl ⁇ adenine, 81 mg, Yield: 35.23%.
  • Chlorochlorosulfonate (a) Chlorosulfonic acid (100 ml, 1.5 mol), bromochlorosilane ( 50 ml, 0.75 mol) was placed in a reaction flask, and the reaction system was slowly heated to reflux for 3 hours. After the reaction was completed, the system was cooled to room temperature, and then poured slowly into 500 g of crushed ice. After the water was melted, it was extracted with dichloromethane (400 ⁇ 2 ml, ), and the organic layer was separated, dried over anhydrous sodium sulfate and filtered. The solvent was distilled off under normal pressure, and the residue was evaporated under reduced pressure to collect 45-50 ° C / 9-10 mmHg fractions. The product was obtained in 30.25 g, yield: 24.4%.
  • N-tert-Butoxycarbonyl-L-proline (3.00 g, 0.0138 mol), sodium hydrogencarbonate (4.59 g, 0.0546 mol) and tetra-n-butylammonium hydrogen sulfate (0.47 g, 0.00138 mol) to 50 ml of water
  • the water salt bath was cooled to 0 ° C, and a solution of chloropurinyl chlorosulfonate (a) (2.78 g, 0.0167 mol) in 14 ml of dichloromethane was slowly added dropwise with vigorous stirring. After the dropwise addition, the system naturally rose to room temperature and reacted for 12 hours.
  • N-tert-butoxycarbonyl-L-leucine was used as a starting material, and was obtained in a similar manner to that of Example 8 to give a white foamy compound (2S, 2's) -9- ⁇ 2-[0,0 '-Bis[(2-tert-butoxycarbonylamino-4-indolylpentanoyloxy)methylene]phosphonohydrazide]ethyl ⁇ adenine 26 mg, yield: 9.56%.
  • ⁇ -tert-butoxy-l-isoleucine was used as a starting material, and was prepared in a similar manner to that of Example 8 to give a white foamy compound (2S, 2's) - 9- ⁇ 2-[0, 0'-bis[(2-tert-butoxycarbonylamino-3-mercaptoloyloxy)methylene]phosphonomethoxy]ethyl ⁇ adenine 85 mg, yield: 15.56%.
  • Example 2 The compound prepared in Example 1 (0.21 g, 0.267 mmol) was dissolved in 1 ml of dry 1,4-dioxane, and the system was cooled to 0 ° C with a salt bath under nitrogen, and slowly added dropwise with stirring at 15%. A solution of hydrogen chloride in 1, 4-dioxane (1 ml, 4 mmol) was incubated for 1 hour, and then reacted at room temperature for 3 hours until the product was fully converted. After standing for 30 minutes, the supernatant in the system was aspirated, and the solid was washed with 5 ⁇ 2 ml of ethyl acetate, and the mixture was allowed to stand for 5 times. The solvent was discarded, and the residue was sufficiently dried to give a white foamy solid, 0.176 g, yield: 95.24% .
  • Acetyl chloride (0.077 ml, 1.06 mmol) and decyl alcohol (0.058 ml, 1.36 mmol) were placed in 1.6 ml of dry ethyl acetate, and the system was cooled to -5 to 0 ° C in a water salt bath for 30 minutes.
  • the compound (30 mg, 0.0379 mmol) of the compound prepared in Example 3 was dissolved in ethyl acetate. After the dropwise addition, the reaction was allowed to stand for 2 hours, and then naturally raised to room temperature for 6 hours until the product was sufficiently converted.
  • Example 14 ( 2S, 2' S ) -9- ⁇ 2- "0,0'-biguanide (2-amino-3-phenylpropionylsulfide)ethyl 1phosphonylmethoxy 1ethyl ⁇ gland Preparation of trihydrochloride (Compound 14) The compound prepared in Example 4 was used as a starting material to give a white powdery product (yield: 84.46%).
  • Example 17 ( 2S, 2' S ) -9- ⁇ 2- "0,0'-bis"(2-amino-3-methylpentanoylthio)ethyl 1phosphonylmethoxy 1ethyl ⁇ gland
  • the trihydrochloride salt (Compound 17 was prepared by the procedure of Example 13 using the compound obtained in Example 7 to give a white fluffy solid, 14 mg, yield: 50.26%.
  • the resultant was dissolved in 2 ml of dry dichloromethane, cooled to 0 ° C in an ice salt bath, and 0.3 ml of pyridine was slowly added thereto, and kept at a low temperature (served below 0 ° C).
  • Example 26 ( 2S, S ) -9- ⁇ 2-"0,0'-biguanide (2-amino-3-methylbutanoyloxy)ethyl 1phosphonomethoxylethyl) gland Preparation of Trihydrochloride (Compound 26) Using the compound prepared in Example 21 as a starting material, a procedure similar to that of Example 11 was afforded to afford white white solid (yield: 13.
  • Example 30 ( 2S, 2' S ) -9- ⁇ 2- ⁇ , 0'-bis((2-amino-4-methylpentanoyloxy)ethyl 1phosphonylmethoxy 1ethyl adenine Preparation of Trihydrochloride (Compound 30) Using the compound prepared in Example 25 as a starting material, a procedure similar to that of Example 11 afforded a pale yellow semi-solid 46 mg, yield: 81.45%.
  • 2 ul of viral DNA was placed in a 48 ⁇ l reaction mixture, including 5 mmol/L MgCl2, 0.2 mmol/L 2.5 U Gold Taq polymerase per dNTP, 0.2 U UNG enzyme and Each was 0.4 mmol/L and the probe was 0.15 mmol/L.
  • the cells were denatured at 95 ° C for 3 min and 30 s, 94 ° C for 20 s, and 60 ° C for 40 s (fluorescence signal detection) for 41 cycles, and finally stored at 4 ° C.
  • the Taqman probe sequence used was detected: 5TAM-CCAGCAGCGCCTCCTCCTGC-3 'TAMARA; Primer sequence: Forward primer: 5'-CCC TCAGGCTCAGGGCATA-3 ', Reverse primer: 5'- CTTCCTGACTGCCGATTGGT-3.
  • Test cell line
  • HepG 2215 cells cited in the Molecular Virus Laboratory of Fudan University.
  • the cell line is obtained by transfecting the receptor cell HepG2 with two head-to-tail HBV DNA whole gene recombinant plasmids, which can stably secrete HBsAg, HBeAg and intact Dane particles in vitro, and can also produce a large number of replication intermediates ( RI).
  • the cells were cultured in DMEM containing 10% fetal bovine serum.
  • the positive control group was adefovir Dipivoxil.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des esters d'acide purine bis-aminés représentés par la formule (I) et des sels inorganiques ou organiques pharmaceutiquement acceptables de ces derniers, où R1 est un groupe amino; R2 est un acide L-amino libre ou protégé par un amino; n est 0 ou 1; X est O ou S. L'invention se rapporte également à la préparation desdits composés et à leur utilisation comme principe actif dans la préparation d'un médicament destiné au traitement de maladies virales. (I)
PCT/CN2006/000663 2006-03-06 2006-04-13 Préparation et utilisation d'esters d'acide purine bis-aminés WO2007101371A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006100244016A CN101033238B (zh) 2006-03-06 2006-03-06 嘌呤类化合物双氨基酸酯的制备方法和用途
CN200610024401.6 2006-03-06

Publications (1)

Publication Number Publication Date
WO2007101371A1 true WO2007101371A1 (fr) 2007-09-13

Family

ID=38474588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/000663 WO2007101371A1 (fr) 2006-03-06 2006-04-13 Préparation et utilisation d'esters d'acide purine bis-aminés

Country Status (2)

Country Link
CN (1) CN101033238B (fr)
WO (1) WO2007101371A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017564A2 (fr) 2011-07-29 2013-02-07 Straitmark Holding Ag Procédé pour la fabrication de composés contenant un groupe alpha-oxy-phosphoré à l'aide de composants p-x
US9908908B2 (en) 2012-08-30 2018-03-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Tenofovir prodrug and pharmaceutical uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009855A1 (fr) * 1993-10-01 1995-04-13 Smithkline Beecham P.L.C. Esters d'amino-acide de penciclovir et de brl 44385
WO1997030051A1 (fr) * 1996-02-16 1997-08-21 Medivir Ab Derives de nucleosides acycliques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009855A1 (fr) * 1993-10-01 1995-04-13 Smithkline Beecham P.L.C. Esters d'amino-acide de penciclovir et de brl 44385
WO1997030051A1 (fr) * 1996-02-16 1997-08-21 Medivir Ab Derives de nucleosides acycliques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALLATORE C. ET AL.: "Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 8, 2001, pages 1053 - 1056 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017564A2 (fr) 2011-07-29 2013-02-07 Straitmark Holding Ag Procédé pour la fabrication de composés contenant un groupe alpha-oxy-phosphoré à l'aide de composants p-x
US9908908B2 (en) 2012-08-30 2018-03-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Tenofovir prodrug and pharmaceutical uses thereof

Also Published As

Publication number Publication date
CN101033238A (zh) 2007-09-12
CN101033238B (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
EP3458455B1 (fr) Nouveaux composés de pyrazine ayant un coupleur d'oxygène, de soufre et d'azote pour le traitement de maladies infectieuses
US8629263B2 (en) Nucleoside phosphoramidates
US8735569B2 (en) Nucleoside phosphoramidates
KR101715981B1 (ko) 뉴클레오사이드 포스포르아미데이트
AU2011235112A1 (en) Nucleoside phosphoramidates
EP2528926A1 (fr) Composés inhibiteurs du virus de l'hépatite c
CA2890676A1 (fr) Phosphonucleosides utiles dans le traitement de troubles viraux
WO2015197006A1 (fr) Composé thioester d'acide aminé substitué, et composition et application de celui-ci
WO2007101371A1 (fr) Préparation et utilisation d'esters d'acide purine bis-aminés
CN101066981A (zh) 非环核苷膦酸酯类化合物及其组合物、制备方法和用途
WO2018082503A1 (fr) Composé hétérocyclique, son procédé de préparation et son application
TWI616453B (zh) Substituted amino acid thioester compounds, compositions and uses thereof
CN101085785B (zh) 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
JP5987255B2 (ja) Ｃ型肝炎阻害化合物
CA2794669C (fr) Phosphoramidates de nucleosides
WO2015096697A1 (fr) Dérivé de phosphonate de nucléoside acyclique et procédé de préparation et son utilisation en science médicale

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06722314

Country of ref document: EP

Kind code of ref document: A1